These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34079085)

  • 1. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
    Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
    Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
    Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dickkopf-related protein 1/cytoskeleton-associated protein 4 signaling activation by
    Luo M; Chen YJ; Xie Y; Wang QR; Xiang YN; Long NY; Yang WX; Zhao Y; Zhou JJ
    World J Gastroenterol; 2022 Dec; 28(47):6769-6787. PubMed ID: 36620343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
    Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.
    Hall C; Ehrlich L; Venter J; O'Brien A; White T; Zhou T; Dang T; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Lairmore TC; Glaser S
    Cancer Lett; 2017 Feb; 386():179-188. PubMed ID: 27894959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
    Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M
    Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
    Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
    Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug.
    Shinno N; Kimura H; Sada R; Takiguchi S; Mori M; Fumoto K; Doki Y; Kikuchi A
    Oncogene; 2018 Jun; 37(26):3471-3484. PubMed ID: 29563607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
    Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression.
    Kimura H; Fumoto K; Shojima K; Nojima S; Osugi Y; Tomihara H; Eguchi H; Shintani Y; Endo H; Inoue M; Doki Y; Okumura M; Morii E; Kikuchi A
    J Clin Invest; 2016 Jul; 126(7):2689-705. PubMed ID: 27322059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.